Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels[1].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.